Evaluation of epidermal growth factor receptor in odontogenic tumors and rare soft tissue tumors by immunohistochemical and fluorescence in situ hybridization methods

Year 2016, Volume: 41 Issue: 2, 316 - 325, 30.06.2016

Kıvılcım Erdoğan Mehmet Deveci Gülfiliz Gönlüşen Aysun Uğuz Melek Ergin Özge Dinigüzel Serdar Özbarlas

Abstract

Purpose: The aim of this study is to investigate the role of epidermal growth factor receptor (EGFR) in odontogenic tumors and rare soft tissue tumors.
Material and Methods: This study includes 28 cases (11 cases of odontogenic tumors and 17 cases of soft tissue tumors) which were diagnosed at Cukurova University Medical Faculty, Department of Pathology between 2002 and 2010. They were evaluated for immunohistochemical staining of EGFR and the presence of genetic abnormality by FISH method. 
Results: Eleven cases were positively stained by immunohistochemistry. Eight cases had genetic abnormality of EGFR gene by FISH method. Nine of eleven odontogenic tumors (81,8%) showed overexpression of EGFR by immunohistochemical method or FISH method. 
Conclusion: Our findings highlight that EGFR plays an important role in chordoma pathogenesis in soft tissue tumors. In addition to odontogenic tumors; two cases of vascular neoplasia, composite and retiform hemangioendothelioma, exhibited EGFR gene amplification. Interestingly, there is no avaliable data about EGFR gene status in these tumors. EGFR can be used for diagnostic purposes. Also, it is a target for anti-EGFR therapy. Therefore, EGFR gene status is a valuable marker for therapeutic management.

Keywords

-

Yumuşak dokunun nadir görülen tümörlerinde ve odontojenik tümörlerde immünohistokimyasal yöntem ve floresan in situ hibridizasyonla epidermal growth faktör reseptör varlığının gösterilmesi

Abstract

Amaç: Bu çalışmada amaç, çeşitli odontojenik tümörler ve nadir görülen yumuşak doku tümörlerinde epidermal growth faktör reseptörün (EGFR) rolünü ortaya koyabilmektir.
Gereç ve Yöntem: Bu çalışmada 2002-2010 yılları arasında Çukurova Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı’nda tanı almış onbir odontojenik tümör olgusu ve onyedi nadir görülen yumuşak doku tümörü olgusu olmak üzere toplam 28 olgu incelenmiştir. Bu olgularda immünohistokimyasal olarak EGFR boyanması ve FISH yöntemi ile genetik anormallik araştırılmıştır. 
Bulgular: Çalışmamızda tüm olgulara immünohistokimyasal olarak uygulanan EGFR ile onbir olgu pozitif boyanmıştır. FISH yöntemi ile ise sekiz olguda genetik anormallik saptanmıştır. Odontojenik tümör olgularımızın dokuzunda (%81,8) immünohistokimyasal yöntemle ya da FISH metodu ile EGFR overekspresyonunun saptanmıştır.
Sonuç: Yumuşak doku tümörlerinde ise kordoma patogenezinde EGFR’nin önemi bulgularımızla tekrar vurgulanmış olup, daha önce EGFR varlığı gösterilmemiş olan odontojenik tümörler ile retiform ve kompozit hemanjioendotelyoma grubu tümörlerde de EGFR’nin rolü olduğu ileri sürülebilir. EGFR tanısal amaçlı kullanılabileceği gibi, anti-EGFR ilaçların hedefini teşkil ettiğinden, hastaların tedavi yönetiminde de oldukça değerlidir.

Keywords

Odontojenik tümör, Yumuşak doku

References

• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1996;46:3-4.
• Dibb NJ, Dilworth SM, Mol CD. Switching on kinases oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer. 2004;4:718-27.
• Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373-98.
• Fischer OM, Hart S, Gcshwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans. 2003;31:1203-8.
• Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg. 2005;131:707-11.
• Dobashi Y, Takei N, Suzuki S, Yoneyama H, Hanawa M, Ooi A. Aberration of epidermal growth factor receptor expression in bone and soft tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol. 2004;17:1497-1505.
• Davies RL, Grosse VA, Kucherlapati R, Bothwell M. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. Proc Natl Acad Sci USA. 1980;77:4188-92.
• Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non small cell lung cancer. Br J Cancer. 1987;55:513-6.
• Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1:1398-402.
• Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA. 1987;84:6899-6903.
• Yamada K, Iwai K, Okada Y, Mori M. Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumors. Virchows Arch A Pathol Anat Histopathol. 1989;415:523-31. 12. Sugiyama K, Yonemura Y, Miyazaki I. Immunohistochemical study of epidermal growth factor and epidermal growth factor receptor in gastric carcinoma. Cancer. 1989;63:1557-61.
• Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and prognosis of bladder cancer. Cancer. 1990;65:1619- 25.
• Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol. 1989;142:1364-8.
• Shiruba RA, Eng LF, Vogel H, Lee YL, Horoupian DS, Ulrich H. Epidermal growth factor receptor in meningiomas is expressed predominantly on endothelial cells. Cancer. 1988;62:2139-44.
• Horsfall DJ, Goldsmith KG, Ricciardelli C, Skinner JM, Tilley WD, Marshall VR. Steroid hormone and epidermal growth factor receptors in meningiomas. Aust N Z J Surg. 1989;59:881-8.
• Mittal K, Pearson J, Demopoulos R. Patterns of mRNA for epidermal growth factor receptor and keratin B-2 in normal cervical epithelium and in cervical intraepithelial neoplasia. Gynecol Oncol. 1990;38:224-9.
• Miyaguchi M, Olofsson J, Hellguist HB. Immunohistochemical study of epidermal growth factor receptor in severe dysplasia and carcinoma in situ of the vocal cords. Acta Otolaryngol. 1991;111:149-52.
• Di Carlo A, Mariano A, Pisano G, Parmeggiani U, Beguinot L, Macchia V. Epidermal growth factor receptor and thyrotropin response in human thyroid tissues. J Endocrinol Invest. 1990;13:293-9.
• Tauchi K, Hori S, Itoh H, Osamura RY, Tokuda Y, Tajima T. Immunohistochemical studies on oncogene products (cerbB2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. Virchows Arch A Pathol Anat Histopathol. 1989;416:65-73.
• Wang DP, Konishi I, Koshiyama M, Nanbu Y, Iwai T, Nonogaki H et al. Immunohistochemical localization of cerbB2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts and common epithelial tumours of the ovary. Virchows Arch A Pathol Anat Histopathol. 1992;421:393-400.
• Shrestha P, Yamada K, Higashiyama H, Takagi H, Mori M. Epidermal growth factor receptor in odontogenic cysts and tumors. J Oral Pathol Med. 1992;21:314-7.
• Vered M, Shohat I, Buchner A. Epidermal growth factor receptor expression in ameloblastoma. Oral Oncology. 2003;138-143.
• Clark P, Peter M, Bastian HL, Krogdahl A. Expression of p53, Ki 67 and EGFR in odontogenic keratocysts before and after decompression. J Oral Pathol Med. 2006;35:568-72.
• Shresta P, Yamada K, Higashiyama H, Takagi H, Mori M. Epidermal growth factor receptor in odontogenic cysts and tumors. J Oral Pathol Med. 1992; 21:314-7.
• Li T-J, Browne RM, Matthews JB. Expression of epidermal growth factor receptors by odontogenic jaw cysts. Virchows Arch A Pathol Anat Histopathol. 1993;423:137-44.
• Ueno S, Miyagawa T, Kaji R, Mushimoto K, Shirasu R. Immunohistochemical investigation of epidermal growth ameloblastomas. J Pathol. 1994;173:33-8. expression in
• Nouri AME, Cannell H, Ong’uti M, Tezabwala BU, Oliver RTD. The possible relevance of the expression of MHC antigens and of EGF receptor in aggressive oral tumours. Int J Oncol. 1997;10:1217- 22.
• Neville BW, Damm DD, Allen CM. Odontogenic cysts and tumors. In: Gnepp DR, editor. Diagnostic surgical pathology of the head and neck. New York: Saunders, 2001:622-33.
• Oliveira MG, Lauxen IS, Chaves ACM, Rados PV, Filho Immunolabeling of Ki 67, EGFR and Survivin in pericoronal follicles, dentigerous cysts and keratocystic odontogenic tumors. Head and Neck Pathol. 2011;5:1-7. epithelium: 31. Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest. 1986;55:588-92.
• Gulkesen KH, Kilicarslan B, Altunbas HA, Karpuzoglu G. EGFR and p53 expression and proliferative activity in parathyroid adenomas: an immunohistochemical study. APMIS. 2001;109:870- 4.
• Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna M, De Rosa G. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res. 2003;82:923-8.
• Yang JL, Hannan MT, Russell PJ, Crowe PJ. Expression of HER1/EGFR protein in human soft tissue sarcomas. Eur J Surg Oncol.. 2006;32:466-68.
• Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM et al. The expression of epidermal growth factor receptor, HER2/Neu, p53 and Ki 67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol. 1996;60:81-8.
• Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC et al. Expression of receptor thyrosine kinases epidermal growth factor receptor and HER2/neu in synovial sarcoma. Cancer. 2005;103:830-8.
• Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist. 2008;13:459-66.
• Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol. 2007;38:914-25.
• Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JMM. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol.
• Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol. 2011;223:336-46.
• Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-55.
• Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor flourescence in situ hybridisation challenge in tumour pathology. J Clin Pathol. 2009;62:314-24.
• Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M et al. EGFR flourescence in situ hybridisation assay: guidelines for application ton on-small-cell lung cancer. J Clin Pathol. 2009;62:970-77.
• Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A. EGFR dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009;22:1328-40.
• Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn. 2008;10:160-8.
• Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E et al. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res. 2004;64:3395-3405.
• Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV et al. Classification of clear cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol. 2003;21:1775-81.
• Schaefer KL, Wai DH, Poremba C, Korsching E, Van Valen F, Ozaki T et al. Characterization of malignant melanoma of soft parts cell line GG-62 by expression analysis using DNA microarrays. Virchows Arch. 2002;440:476-84.
• Schaefer KL, Brachwitz K, Braun Y, Diallo R, Wai DH, Zahn S et al. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia. 2006;8:613-22.
• Katayama R, Huelsmeyer MK, Marr AK, Kurzman ID, Thamm DH, Vail DM. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine- associated sarcoma. Cancer Chemother Pharmacol. 2004;54:25-33.
• Tamborini E, Banadiman L, Greco A, Gronchi A, Riva C, Bertulli R et al. Expression of ligand- activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res. 2004;10:938-43.
• Beech D, Pollock RE, Tsan R, Radinsky R. Epidermal growth factor receptor and insuline-like growth factor-I receptor expression and function in human soft tissue sarcoma cells. Int J Oncol. 1998;12:329-36.
• Beham AW, Schaefer IM, Schüler P, Cameron S, Ghadimi BM. Gastrointestinal stromal tumors. Int J Colorectal Dis. 2012;27:689-700.
• Kersting C, Packeisen J, Leidinger B, Brandt B, Wasielewski R, Winkelmann W et al. Pitfalls in immunohistochemical expression in soft tissue sarcomas. J Clin Pathol. 2006;59:585-90. of EGFR
• Jha P, Sarkar C, Pathak P, Sharma MC, Kale SS, Gupta D et al. Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management. Diagn Mol Pathol. 2011;20:40-7.
• Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144-52.
• Scheie D, Andresen PA, Cvancarova M, Bİ AS, Helseth E, Skullerud K et al. Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol. 2006;30:828-37.
• Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW.. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci. 2003;8:1-9.
• Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol. 2009;11:737-46.
• Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigate neuropathology. Brain Pathol. 2002;12:67-86.
• Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol. 2008;67:1-15.
• Schurter MJ, LeBrun DP, Harrison KJ. Improved technique for fluorescence in situ hybridisation analysis of isolated nuclei from archival, B5 or formalin fixed, paraffin wax embedded tissue. J Clin Pathol: Mol Pathol. 2002;55:121-4.
• Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MMet al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin embedded prostatic adenocarcinoma specimens. Am J Pathol.
• Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi OP, Isola JJ. Improved technique for analysis of formalin-fixed, paraffin-embedded tumours by fluorescence in situ hybridization. Cytometry. 1994;16:93-9
• DiFrancesco LM, Murthy SK, Luider J, Demetrick DJ. fluorescence in situ hybridization and flow cytometric cell cycle analysis of purified nuclei from paraffin sections. Mod Pathol. 2000;13:705-11.